> top > docs > PubMed:16720068 > annotations

PubMed:16720068 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-entities-OrganismTaxon-PD

Id Subject Object Predicate Lexical cue db_id
T1 119-122 OrganismTaxon denotes man NCBItxid:9606

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-104 Sentence denotes Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
T2 105-248 Sentence denotes A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
T3 249-339 Sentence denotes Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
T4 340-506 Sentence denotes On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
T5 507-649 Sentence denotes The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
T6 650-829 Sentence denotes Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
T7 830-900 Sentence denotes The patient received bromocriptine and diazepam to treat his symptoms.
T8 901-999 Sentence denotes 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
T9 1000-1181 Sentence denotes This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
T10 1182-1395 Sentence denotes The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
T11 1396-1492 Sentence denotes The involvement of physiologic and environmental aspects specific to this patient was suspected.
T12 1493-1651 Sentence denotes Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
T13 1652-1761 Sentence denotes Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
2970 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome MESH:D009459
2971 78-88 ChemicalEntity denotes paroxetine MESH:D017374
2972 93-103 ChemicalEntity denotes alprazolam MESH:D000525
2973 119-122 OrganismTaxon denotes man NCBITaxon:9606
2974 128-147 DiseaseOrPhenotypicFeature denotes depressive symptoms MESH:D003866
2975 166-177 DiseaseOrPhenotypicFeature denotes psychiatric MESH:D001523
2976 194-202 DiseaseOrPhenotypicFeature denotes insomnia MESH:D007319
2977 204-220 DiseaseOrPhenotypicFeature denotes loss of appetite MESH:D001068
2978 238-247 DiseaseOrPhenotypicFeature denotes agitation MESH:D011595
2979 306-316 ChemicalEntity denotes paroxetine MESH:D017374
2980 328-338 ChemicalEntity denotes alprazolam MESH:D000525
2981 359-369 ChemicalEntity denotes paroxetine MESH:D017374
2982 374-384 ChemicalEntity denotes alprazolam MESH:D000525
2983 400-407 OrganismTaxon denotes patient NCBITaxon:9606
2984 425-448 DiseaseOrPhenotypicFeature denotes psychomotor retardation MESH:D011596
2985 477-492 DiseaseOrPhenotypicFeature denotes muscle rigidity MESH:D009127
2986 498-505 DiseaseOrPhenotypicFeature denotes tremors MESH:D014202
2987 511-518 OrganismTaxon denotes patient NCBITaxon:9606
2988 525-530 DiseaseOrPhenotypicFeature denotes fever MESH:D005334
2989 625-648 DiseaseOrPhenotypicFeature denotes extrapyramidal symptoms MESH:D001480
2990 690-712 ChemicalEntity denotes creatine phosphokinase MESH:D003402
2991 726-752 ChemicalEntity denotes aspartate aminotransferase MESH:D001219
2992 765-789 ChemicalEntity denotes alanine aminotransferase MESH:D000410
2993 834-841 OrganismTaxon denotes patient NCBITaxon:9606
2994 851-864 ChemicalEntity denotes bromocriptine MESH:D001971
2995 869-877 ChemicalEntity denotes diazepam MESH:D003975
2996 919-924 DiseaseOrPhenotypicFeature denotes fever MESH:D005334
2997 945-952 OrganismTaxon denotes patient NCBITaxon:9606
2998 961-964 ChemicalEntity denotes CPK MESH:D003402
2999 1005-1012 OrganismTaxon denotes patient NCBITaxon:9606
3000 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome MESH:D009459
3001 1072-1075 DiseaseOrPhenotypicFeature denotes NMS MESH:D009459
3002 1102-1105 DiseaseOrPhenotypicFeature denotes NMS MESH:D009459
3003 1145-1155 ChemicalEntity denotes paroxetine MESH:D017374
3004 1160-1170 ChemicalEntity denotes alprazolam MESH:D000525
3005 1314-1321 OrganismTaxon denotes patient NCBITaxon:9606
3006 1324-1327 DiseaseOrPhenotypicFeature denotes NMS MESH:D009459
3007 1470-1477 OrganismTaxon denotes patient NCBITaxon:9606
3008 1518-1521 DiseaseOrPhenotypicFeature denotes NMS MESH:D009459
3009 1549-1559 DiseaseOrPhenotypicFeature denotes depressive MESH:D003866
3010 1560-1568 OrganismTaxon denotes patients NCBITaxon:9606
3011 1598-1609 DiseaseOrPhenotypicFeature denotes dehydration MESH:D003681
3012 1611-1620 DiseaseOrPhenotypicFeature denotes agitation MESH:D011595
3013 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition MESH:D044342
3014 1725-1733 OrganismTaxon denotes patients NCBITaxon:9606
3015 1750-1760 DiseaseOrPhenotypicFeature denotes depression MESH:D003866

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome 0019790
T2 194-202 DiseaseOrPhenotypicFeature denotes insomnia 0013600
T3 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome 0019790

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 31-39 GeneOrGeneProduct denotes syndrome
T2 110-114 GeneOrGeneProduct denotes year
T3 128-138 GeneOrGeneProduct denotes depressive
T4 271-280 GeneOrGeneProduct denotes initiated
T5 303-305 GeneOrGeneProduct denotes mg
T6 325-327 GeneOrGeneProduct denotes mg
T7 418-424 GeneOrGeneProduct denotes marked
T8 477-483 GeneOrGeneProduct denotes muscle
T9 484-492 GeneOrGeneProduct denotes rigidity
T10 498-505 GeneOrGeneProduct denotes tremors
T11 519-524 GeneOrGeneProduct denotes had a
T12 603-605 GeneOrGeneProduct denotes mg
T13 661-666 GeneOrGeneProduct denotes tests
T14 726-752 GeneOrGeneProduct denotes aspartate aminotransferase
T15 765-789 GeneOrGeneProduct denotes alanine aminotransferase
T16 815-817 GeneOrGeneProduct denotes mg
T17 818-820 GeneOrGeneProduct denotes ml
T18 908-913 GeneOrGeneProduct denotes later
T19 1062-1070 GeneOrGeneProduct denotes syndrome
T20 1106-1110 GeneOrGeneProduct denotes like
T21 1248-1256 GeneOrGeneProduct denotes was 6 in
T22 1261-1265 GeneOrGeneProduct denotes case
T23 1280-1288 GeneOrGeneProduct denotes probable
T24 1328-1332 GeneOrGeneProduct denotes like
T25 1390-1394 GeneOrGeneProduct denotes case
T26 1506-1517 GeneOrGeneProduct denotes factors for
T27 1549-1559 GeneOrGeneProduct denotes depressive
T28 1652-1659 GeneOrGeneProduct denotes Careful
T29 1701-1706 GeneOrGeneProduct denotes cases
T30 1750-1760 GeneOrGeneProduct denotes depression

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 31-39 GeneOrGeneProduct denotes syndrome
T2 477-483 GeneOrGeneProduct denotes muscle
T3 726-752 GeneOrGeneProduct denotes aspartate aminotransferase
T4 765-789 GeneOrGeneProduct denotes alanine aminotransferase
T5 1062-1070 GeneOrGeneProduct denotes syndrome
T6 1106-1110 GeneOrGeneProduct denotes like
T7 1280-1288 GeneOrGeneProduct denotes probable
T8 1328-1332 GeneOrGeneProduct denotes like

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T2 128-138 DiseaseOrPhenotypicFeature denotes depressive DISEASE
T3 194-202 DiseaseOrPhenotypicFeature denotes insomnia D007319
T4 425-448 DiseaseOrPhenotypicFeature denotes psychomotor retardation DISEASE
T5 450-464 DiseaseOrPhenotypicFeature denotes disorientation D003221
T6 477-492 DiseaseOrPhenotypicFeature denotes muscle rigidity D009127
T7 498-505 DiseaseOrPhenotypicFeature denotes tremors D014202
T8 525-530 DiseaseOrPhenotypicFeature denotes fever D005334
T9 919-924 DiseaseOrPhenotypicFeature denotes fever D005334
T10 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T11 1186-1207 DiseaseOrPhenotypicFeature denotes adverse drug reaction D064420
T12 1549-1559 DiseaseOrPhenotypicFeature denotes depressive DISEASE
T13 1598-1609 DiseaseOrPhenotypicFeature denotes dehydration D003681
T14 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition D044342
T15 1750-1760 DiseaseOrPhenotypicFeature denotes depression DISEASE

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T1 726-752 GeneOrGeneProduct denotes aspartate aminotransferase
T2 765-789 GeneOrGeneProduct denotes alanine aminotransferase
T3 1280-1288 GeneOrGeneProduct denotes probable

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome 0019790
T2 194-202 DiseaseOrPhenotypicFeature denotes insomnia 0013600
T3 719-721 DiseaseOrPhenotypicFeature denotes IU 0006806
T4 758-760 DiseaseOrPhenotypicFeature denotes IU 0006806
T5 794-796 DiseaseOrPhenotypicFeature denotes IU 0006806
T6 993-995 DiseaseOrPhenotypicFeature denotes IU 0006806
T7 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome 0019790
T8 1072-1075 DiseaseOrPhenotypicFeature denotes NMS 0019790
T9 1102-1105 DiseaseOrPhenotypicFeature denotes NMS 0019790
T10 1120-1123 DiseaseOrPhenotypicFeature denotes can 0012833
T11 1324-1327 DiseaseOrPhenotypicFeature denotes NMS 0019790
T12 1518-1521 DiseaseOrPhenotypicFeature denotes NMS 0019790
T13 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition 0006873
T14 1750-1760 DiseaseOrPhenotypicFeature denotes depression 0002050

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T2 128-147 DiseaseOrPhenotypicFeature denotes depressive symptoms DISEASE
T3 166-177 DiseaseOrPhenotypicFeature denotes psychiatric DISEASE
T4 194-202 DiseaseOrPhenotypicFeature denotes insomnia D007319
T5 204-220 DiseaseOrPhenotypicFeature denotes loss of appetite DISEASE
T6 238-247 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T7 425-448 DiseaseOrPhenotypicFeature denotes psychomotor retardation DISEASE
T8 450-464 DiseaseOrPhenotypicFeature denotes disorientation D003221
T9 477-492 DiseaseOrPhenotypicFeature denotes muscle rigidity D009127
T10 498-505 DiseaseOrPhenotypicFeature denotes tremors D014202
T11 525-530 DiseaseOrPhenotypicFeature denotes fever D005334
T12 625-648 DiseaseOrPhenotypicFeature denotes extrapyramidal symptoms DISEASE
T13 919-924 DiseaseOrPhenotypicFeature denotes fever D005334
T14 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T15 1072-1075 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T17 1102-1105 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T19 1186-1207 DiseaseOrPhenotypicFeature denotes adverse drug reaction D064420
T20 1324-1327 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T22 1518-1521 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T24 1549-1559 DiseaseOrPhenotypicFeature denotes depressive DISEASE
T25 1598-1609 DiseaseOrPhenotypicFeature denotes dehydration D003681
T26 1611-1620 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T27 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition D044342
T28 1750-1760 DiseaseOrPhenotypicFeature denotes depression DISEASE

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T2 128-147 DiseaseOrPhenotypicFeature denotes depressive symptoms DISEASE
T3 166-177 DiseaseOrPhenotypicFeature denotes psychiatric DISEASE
T4 194-202 DiseaseOrPhenotypicFeature denotes insomnia D007319
T5 204-220 DiseaseOrPhenotypicFeature denotes loss of appetite DISEASE
T6 238-247 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T7 425-448 DiseaseOrPhenotypicFeature denotes psychomotor retardation DISEASE
T8 450-464 DiseaseOrPhenotypicFeature denotes disorientation D003221
T9 477-492 DiseaseOrPhenotypicFeature denotes muscle rigidity D009127
T10 498-505 DiseaseOrPhenotypicFeature denotes tremors D014202
T11 525-530 DiseaseOrPhenotypicFeature denotes fever D005334
T12 625-648 DiseaseOrPhenotypicFeature denotes extrapyramidal symptoms DISEASE
T13 919-924 DiseaseOrPhenotypicFeature denotes fever D005334
T14 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T15 1072-1075 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T17 1102-1105 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T19 1324-1327 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T21 1518-1521 DiseaseOrPhenotypicFeature denotes NMS DISEASE|D009459
T23 1549-1559 DiseaseOrPhenotypicFeature denotes depressive DISEASE
T24 1598-1609 DiseaseOrPhenotypicFeature denotes dehydration D003681
T25 1611-1620 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T26 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition D044342
T27 1750-1760 DiseaseOrPhenotypicFeature denotes depression DISEASE

LitCoin-NCBITaxon-2

Id Subject Object Predicate Lexical cue
T1 119-122 OrganismTaxon denotes man
T2 400-407 OrganismTaxon denotes patient
T3 511-518 OrganismTaxon denotes patient
T4 834-841 OrganismTaxon denotes patient
T5 1005-1012 OrganismTaxon denotes patient
T6 1470-1477 OrganismTaxon denotes patient
T7 1560-1568 OrganismTaxon denotes patients
T8 1725-1733 OrganismTaxon denotes patients

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 9-20 ChemicalEntity denotes neuroleptic ChemicalEntity
T2 78-88 ChemicalEntity denotes paroxetine D017374|http://purl.obolibrary.org/obo/CHEBI_7936
T4 93-103 ChemicalEntity denotes alprazolam D000525|http://purl.obolibrary.org/obo/CHEBI_2611
T6 306-316 ChemicalEntity denotes paroxetine D017374|http://purl.obolibrary.org/obo/CHEBI_7936
T8 328-338 ChemicalEntity denotes alprazolam D000525|http://purl.obolibrary.org/obo/CHEBI_2611
T10 359-369 ChemicalEntity denotes paroxetine D017374|http://purl.obolibrary.org/obo/CHEBI_7936
T12 374-384 ChemicalEntity denotes alprazolam D000525|http://purl.obolibrary.org/obo/CHEBI_2611
T14 690-712 ChemicalEntity denotes creatine phosphokinase D003402
T15 726-752 ChemicalEntity denotes aspartate aminotransferase D001219
T16 765-789 ChemicalEntity denotes alanine aminotransferase D000410
T17 851-864 ChemicalEntity denotes bromocriptine D001971|http://purl.obolibrary.org/obo/CHEBI_3181
T19 869-877 ChemicalEntity denotes diazepam D003975|http://purl.obolibrary.org/obo/CHEBI_49575
T21 961-964 ChemicalEntity denotes CPK ChemicalEntity
T22 1040-1051 ChemicalEntity denotes neuroleptic ChemicalEntity
T23 1145-1155 ChemicalEntity denotes paroxetine D017374|http://purl.obolibrary.org/obo/CHEBI_7936
T25 1160-1170 ChemicalEntity denotes alprazolam D000525|http://purl.obolibrary.org/obo/CHEBI_2611

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T25 1160-1170 ChemicalEntity denotes alprazolam http://purl.obolibrary.org/obo/CHEBI_2611|D000525
T23 1145-1155 ChemicalEntity denotes paroxetine http://purl.obolibrary.org/obo/CHEBI_7936|D017374
T22 1040-1051 ChemicalEntity denotes neuroleptic ChemicalEntity
T21 961-964 ChemicalEntity denotes CPK ChemicalEntity
T19 869-877 ChemicalEntity denotes diazepam http://purl.obolibrary.org/obo/CHEBI_49575|D003975
T17 851-864 ChemicalEntity denotes bromocriptine http://purl.obolibrary.org/obo/CHEBI_3181|D001971
T16 765-789 ChemicalEntity denotes alanine aminotransferase D000410
T15 726-752 ChemicalEntity denotes aspartate aminotransferase D001219
T14 690-712 ChemicalEntity denotes creatine phosphokinase D003402
T12 374-384 ChemicalEntity denotes alprazolam http://purl.obolibrary.org/obo/CHEBI_2611|D000525
T10 359-369 ChemicalEntity denotes paroxetine http://purl.obolibrary.org/obo/CHEBI_7936|D017374
T8 328-338 ChemicalEntity denotes alprazolam http://purl.obolibrary.org/obo/CHEBI_2611|D000525
T6 306-316 ChemicalEntity denotes paroxetine http://purl.obolibrary.org/obo/CHEBI_7936|D017374
T4 93-103 ChemicalEntity denotes alprazolam http://purl.obolibrary.org/obo/CHEBI_2611|D000525
T2 78-88 ChemicalEntity denotes paroxetine http://purl.obolibrary.org/obo/CHEBI_7936|D017374
T1 9-20 ChemicalEntity denotes neuroleptic ChemicalEntity
T3 1280-1288 GeneOrGeneProduct denotes probable
T32572 765-789 GeneOrGeneProduct denotes alanine aminotransferase
T25222 726-752 GeneOrGeneProduct denotes aspartate aminotransferase
T27 1750-1760 DiseaseOrPhenotypicFeature denotes depression DISEASE
T26 1622-1634 DiseaseOrPhenotypicFeature denotes malnutrition D044342
T84255 1611-1620 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T24 1598-1609 DiseaseOrPhenotypicFeature denotes dehydration D003681
T79548 1549-1559 DiseaseOrPhenotypicFeature denotes depressive DISEASE
T85198 1518-1521 DiseaseOrPhenotypicFeature denotes NMS D009459|DISEASE
T26589 1324-1327 DiseaseOrPhenotypicFeature denotes NMS D009459|DISEASE
T11865 1102-1105 DiseaseOrPhenotypicFeature denotes NMS D009459|DISEASE
T34125 1072-1075 DiseaseOrPhenotypicFeature denotes NMS D009459|DISEASE
T19169 1040-1070 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T13 919-924 DiseaseOrPhenotypicFeature denotes fever D005334
T61844 625-648 DiseaseOrPhenotypicFeature denotes extrapyramidal symptoms DISEASE
T11 525-530 DiseaseOrPhenotypicFeature denotes fever D005334
T38641 498-505 DiseaseOrPhenotypicFeature denotes tremors D014202
T9 477-492 DiseaseOrPhenotypicFeature denotes muscle rigidity D009127
T64274 450-464 DiseaseOrPhenotypicFeature denotes disorientation D003221
T7 425-448 DiseaseOrPhenotypicFeature denotes psychomotor retardation DISEASE
T52166 238-247 DiseaseOrPhenotypicFeature denotes agitation DISEASE
T5 204-220 DiseaseOrPhenotypicFeature denotes loss of appetite DISEASE
T11520 194-202 DiseaseOrPhenotypicFeature denotes insomnia D007319
T13588 166-177 DiseaseOrPhenotypicFeature denotes psychiatric DISEASE
T9421 128-147 DiseaseOrPhenotypicFeature denotes depressive symptoms DISEASE
T89746 9-39 DiseaseOrPhenotypicFeature denotes neuroleptic malignant syndrome D009459
T65943 1725-1733 OrganismTaxon denotes patients
T26138 1560-1568 OrganismTaxon denotes patients
T61529 1470-1477 OrganismTaxon denotes patient
T80804 1005-1012 OrganismTaxon denotes patient
T97887 834-841 OrganismTaxon denotes patient
T47905 511-518 OrganismTaxon denotes patient
T13054 400-407 OrganismTaxon denotes patient
T75712 119-122 OrganismTaxon denotes man

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 128-138 HP_0000716 denotes depressive
T2 194-202 HP_0100785 denotes insomnia
T3 238-247 HP_0000713 denotes agitation
T4 425-448 HP_0001263 denotes psychomotor retardation
T5 450-464 HP_0001289 denotes disorientation
T6 477-492 HP_0002063 denotes muscle rigidity
T7 484-492 HP_0002063 denotes rigidity
T8 498-505 HP_0001337 denotes tremors
T9 525-530 HP_0001945 denotes fever
T10 625-648 HP_0002071 denotes extrapyramidal symptoms
T11 919-924 HP_0001945 denotes fever
T12 1549-1559 HP_0000716 denotes depressive
T13 1598-1609 HP_0001944 denotes dehydration
T14 1611-1620 HP_0000713 denotes agitation
T15 1622-1634 HP_0004395 denotes malnutrition
T16 1750-1760 HP_0000716 denotes depression

PubCasesHPO

Id Subject Object Predicate Lexical cue
AB1 194-202 HP:0100785 denotes insomnia
AB2 238-247 HP:0000713 denotes agitation
AB3 484-492 HP:0002063 denotes rigidity
AB4 498-505 HP:0001337 denotes tremors
AB5 525-530 HP:0001945 denotes fever
AB6 919-924 HP:0001945 denotes fever
AB7 1598-1609 HP:0001944 denotes dehydration
AB8 1611-1620 HP:0000713 denotes agitation
AB9 1622-1634 HP:0004395 denotes malnutrition
AB10 1750-1760 HP:0000716 denotes depression

PubCasesORDO

Id Subject Object Predicate Lexical cue
TI1 9-39 ORDO:94093 denotes neuroleptic malignant syndrome
AB1 1040-1070 ORDO:94093 denotes neuroleptic malignant syndrome

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-104 Sentence denotes Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
TextSentencer_T2 105-248 Sentence denotes A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
TextSentencer_T3 249-339 Sentence denotes Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
TextSentencer_T4 340-506 Sentence denotes On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
TextSentencer_T5 507-649 Sentence denotes The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
TextSentencer_T6 650-829 Sentence denotes Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
TextSentencer_T7 830-900 Sentence denotes The patient received bromocriptine and diazepam to treat his symptoms.
TextSentencer_T8 901-999 Sentence denotes 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
TextSentencer_T9 1000-1181 Sentence denotes This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
TextSentencer_T10 1182-1395 Sentence denotes The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
TextSentencer_T11 1396-1492 Sentence denotes The involvement of physiologic and environmental aspects specific to this patient was suspected.
TextSentencer_T12 1493-1651 Sentence denotes Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
TextSentencer_T13 1652-1761 Sentence denotes Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.
T1 0-104 Sentence denotes Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
T2 105-248 Sentence denotes A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
T3 249-339 Sentence denotes Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
T4 340-506 Sentence denotes On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
T5 507-649 Sentence denotes The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
T6 650-829 Sentence denotes Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
T7 830-900 Sentence denotes The patient received bromocriptine and diazepam to treat his symptoms.
T8 901-999 Sentence denotes 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
T9 1000-1181 Sentence denotes This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
T10 1182-1395 Sentence denotes The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
T11 1396-1492 Sentence denotes The involvement of physiologic and environmental aspects specific to this patient was suspected.
T12 1493-1651 Sentence denotes Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
T13 1652-1761 Sentence denotes Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 955-960 http://purl.obolibrary.org/obo/UBERON_0001977 denotes serum
PD-UBERON-AE-B_T2 561-566 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood